Update June 26, 2020: VGXI and GeneOne are pleased with the court’s decision in our favor protecting our company’s intellectual property rights. We have always been willing to manufacture any vaccine candidate for Covid-19, and want to help find a cure.

Original Post on June 04, 2020: VGXI was surprised by Inovio’s court filing, as VGXI has manufactured Inovio’s COVID-19 vaccine, and continues the project to this day.  Moreover, the allegations in the complaint are inaccurate, and the court has already denied Inovio’s motion to seal the record from the public.

VGXI has been and continues to be a good manufacturing partner to Inovio.  Inovio was only able to start its clinical study in April 2020 due to VGXI’s efforts and collaboration. VGXI has already manufactured sufficient doses of the vaccine candidate for Inovio’s planned large-scale COVID-19 clinical trials, and VGXI continues manufacturing Inovio’s COVID-19 vaccine candidate.  VGXI and its employees are committed to fight COVID-19, and are willing to work with any company, government agency, and not-for profit organization to fight this pandemic.

For reasons unknown to VGXI, rather than continue working with VGXI to achieve accelerated manufacturing levels, Inovio has instead filed this court action to try to take VGXI’s intellectual property.  Inovio is in breach of its obligations under the Supply Agreement, and VGXI provided Inovio a notice of termination on May 7, 2020.  For these and other reasons, VGXI is eager to have this matter resolved in a court of law.